Please assess the completion status of the following clinical trial:

Trial Title: Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed incurable non-small cell lung cancer that harbors an activating mutation in EGFR, MET, BRAF, V600E, RET, HER2, translocation in Alk, or translocation in ROS-1~* Patients must be receiving treatment or planning to start treatment with a tyrosine kinase inhibitor targeting the activated gene~* Patients may not be receiving the treatment targeting the activated gene as part of a clinical treatment trial other than the Precision Oncology Trial~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3~* Total bilirubin =\< 1.5 X institutional upper limit of normal~* Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine transaminase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional upper limit of normal~* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately~* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document~Exclusion Criteria:~* Emergent need for palliative radiation~* Patients may not be receiving any other investigational agents for the treatment of non-small cell lung cancer~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant women are excluded; breastfeeding should be discontinued

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (nivolumab, pembrolizumab) (Type: EXPERIMENTAL): Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II (kinase inhibitor, chemotherapy, immunotherapy) (Type: EXPERIMENTAL): Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
- Arm III (kinase inhibitor, targeted therapy, other treatment) (Type: EXPERIMENTAL): Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).